Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the ...
2h
Hosted on MSNWhat To Expect When IBD 50's No. 2, Hims & Hers, Reports Amid The Semaglutide BattleCompounding pharmacy and IBD 50 newcomer Hims & Hers Health is expected late Monday to report bullish earnings and sales ...
Ensho Therapeutics has presented additional data supporting NSHO-101, also referred to as EA1080, as an oral one-time-a-day ...
Hosted on MSN19h
Celltrion booth at inflammatory bowel disease research gatheringCelltrion booth at inflammatory bowel disease research gathering Visitors attend a presentation by South Korean ...
Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...
Factors linked to C difficile infection in patients with IBD include IBD activity prior to infection, shorter disease ...
Better cardiovascular safety and lower risk of all-cause mortality was observed among older adult patients with IBD who received ustekinumab vs vedolizumab.
Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...
Major Cause of Inflammatory Bowel Disease Discovered June 5, 2024 — Researchers have discovered a new biological pathway that is a principal driver of inflammatory bowel disease (IBD ...
It basically kept getting passed off as, like, anxiety or stress since I was meeting someone new and eating new foods...” ...
Researchers have found a compound in ginger, called furanodienone (FDN), that selectively binds to and regulates a nuclear receptor involved in inflammatory bowel disease (IBD). While researchers have ...
Switching from IV to subcutaneous infliximab maintenance therapy is associated with high treatment persistence and a stable ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results